Efficacy of Oral Zinc Sulfate on Clearance of Cervical Low-grade Sqaumous Intraepithelial Lesion (LSIL), Randomized Control trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250406002

Enrollment

110

Registered

2025-04-06

Start date

2025-05-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Low-grade Sqaumous Intraepithelial Lesion (LSIL) Oral Zinc Sulfate LSIL

Interventions

Oral Zinc Sulfate 110 mg per oral twice a day for 12 weeks,No drug or placebo

Active Comparator Drug,No Intervention No treatment

Oral Zinc Sulfate,Standard of Care

Eligibility

Sex/Gender

Female

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Histological diagnosis of Cervical Low-grade Sqaumous Intraepithelial Lesion (LSIL) from colposcopy-directed biopsy

Exclusion criteria

Exclusion criteria: 1 Breastfeeding 2 History of Oral Zinc Sulfate with use in 12 weeks 3 History of Autoimmune diseases 4 History of HIV Infection 5 History of allergic to Oral Zinc Sulfate 6 History of contraindicated to Oral Zinc Sulfate

Design outcomes

Primary

Measure	Time frame
Cervical Cytology At 12 and 24 weeks after start of intervention Conventional Pap Smear	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactTeerat Wishwaitayavej

Bhumibol Adulyadej Hospital

dr.kimkuma@gmail.com6625347000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026